Incyte Corporation
pentostatin(Incyte Corporation)은 Chronic Myeloproliferative Disorders 표적 세포·유전자 치료로, Chronic Myeloproliferative Disorders; Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targets the cell surface antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 96% (ClinicalTrials.gov NCT01024010). PK: t½ 5.7 h. 차별점: novel approach to the adoptive T cell therapy of cancer.
Chronic Myeloproliferative Disorders
Chronic Myeloproliferative Disorders; Leukemia
Discontinued
NK cells) combined with the absence of both humoral and cellular im
novel approach to the adoptive T cell therapy of cancer
targets the cell surface antigen
cytokine release
Apoptosis was measured and cell cycle analyzed
biomarker of disease activity and a potential therapeutic target
resistance to obesity and improves metabolic health
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Incyte Corporation
pentostatin(Incyte Corporation)은 Chronic Myeloproliferative Disorders 표적 세포·유전자 치료로, Chronic Myeloproliferative Disorders; Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targets the cell surface antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 96% (ClinicalTrials.gov NCT01024010). PK: t½ 5.7 h. 차별점: novel approach to the adoptive T cell therapy of cancer.
Chronic Myeloproliferative Disorders
Chronic Myeloproliferative Disorders; Leukemia
Discontinued
NK cells) combined with the absence of both humoral and cellular im
novel approach to the adoptive T cell therapy of cancer
targets the cell surface antigen
cytokine release
Apoptosis was measured and cell cycle analyzed
biomarker of disease activity and a potential therapeutic target
resistance to obesity and improves metabolic health
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.